KA NASDAQ
Kineta, Inc.
1W: +0.7%
1M: -19.7%
3M: -15.5%
1Y: -83.1%
3Y: -96.1%
5Y: -97.6%
$0.57
Last traded 2024-10-14 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$7.0M
52W Range0.3339-5.39
Volume480,683
Avg Volume508,865
Beta0.57
Dividend—
Analyst Ratings
Company Info
CEOCraig W. Philips
Employees11
SectorHealthcare
IndustryBiotechnology
IPO Date2016-02-11
Websitekinetabio.com
219 Terry Ave. N
Seattle, WA 98109
US
Seattle, WA 98109
US
206 378 0400
About Kineta, Inc.
Kineta, Inc. is a clinical-stage biotechnology firm dedicated to developing immunotherapies, with a focus on oncology, neuroscience, and biodefense applications. The company engages in partnerships with a variety of entities, including private companies, government bodies, and other industry stakeholders. Among its significant strategic collaborators are Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Established in 2007, Kineta, Inc. was previously known as Lecura, Inc. and has its base of operations in Seattle, Washington.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Peters Richard | A-Award | 12,500 | $0.61 | 2024-09-04 |
| Iadonato Shawn | A-Award | 12,500 | $0.61 | 2024-09-04 |
| Foote Marion R | A-Award | 12,500 | $0.61 | 2024-09-04 |
| Dylla Scott J. | A-Award | 12,500 | $0.61 | 2024-09-04 |
| Drapkin Kimberlee C | A-Award | 12,500 | $0.61 | 2024-09-04 |